Compare Abbott Laboratories (ABT) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Palo Alto Networks Inc — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while Palo Alto Networks Inc trades at $320.71 (market cap $274.69B). The key difference: Palo Alto Networks Inc is the larger of the two by market cap, and Abbott Laboratories pays a 2.63% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals.
| ABT | PANW | |
|---|---|---|
Market Cap | $166.94B | $274.69B |
Sector | Health | Technology |
52-Week High | $136.62 | $357.53 |
52-Week Low | $82.57 | $141.67 |
Enterprise Value | $193.69B | $273.65B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
Palo Alto Networks (PANW) trades at $337.04, down 3.17% today but remains near all-time highs with strong bullish momentum. The stock has surged over 150% from yearly lows, driven by robust cybersecurity demand and AI-driven security solutions. Recent earnings consistently beat expectations, with Q1 2026 EPS of $0.85 surpassing the $0.793 estimate. Revenue growth remains solid at $9.22B for 2025, though valuation multiples appear elevated with a P/E of 310.9 and P/S of 24.82. Technical indicators show mixed signals with moving averages bullish but RSI levels suggesting overbought conditions.
Outlook: PANW benefits from durable growth drivers including platformization and AI cybersecurity adoption, with analysts projecting a 19-23% upside to consensus targets. Risks include premium valuation sensitivity, integration costs from acquisitions, and competitive pressures. The stock's trajectory hinges on execution of its $20B NGS ARR target by 2030 and maintaining industry leadership amid rising AI threats. Near-term support lies at $324, with resistance at $371.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
